CDK6 and colorectal cancer: In colorectal cancer models, analog 4i—a nortopsentin derivative—exhibited particularly potent activity, downregulating CDK2, CDK4, and CDK6 expression and suppressing CDK6 enzymatic activity to induce G1-phase arrest [17].